Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia-Reference-Cited by-同舟云学术

Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia

Published:2014-06-19 Issue:25 Volume:123 Page:3951-3962
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Herrmann Harald¹,Sadovnik Irina²,Cerny-Reiterer Sabine¹²,Rülicke Thomas³,Stefanzl Gabriele²,Willmann Michael⁴,Hoermann Gregor⁵,Bilban Martin⁵,Blatt Katharina²,Herndlhofer Susanne²,Mayerhofer Matthias⁵,Streubel Berthold⁶,Sperr Wolfgang R.¹²,Holyoake Tessa L.⁷,Mannhalter Christine⁵,Valent Peter¹²

Affiliation:

1. Ludwig Boltzmann Cluster Oncology, and

2. Department of Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria;

3. Institute of Laboratory Animal Science and

4. Department of Companion Animals and Horses, Clinic for Internal Medicine and Infectious Diseases, University of Veterinary Medicine Vienna, Vienna, Austria;

5. Department of Laboratory Medicine, and

6. Institute of Gynecology & Obstetrics, Medical University of Vienna, Vienna, Austria; and

7. College of Medical, Veterinary & Life Sciences, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom

Abstract

Key Points DPPIV (CD26) is a new specific marker of CML LSC that aids CML diagnostics and the measurement, characterization, and purification of LSC. DPPIV on CML LSC degrades SDF-1 and thereby promotes the niche-escape of LSC, which may contribute to extramedullary myeloproliferation in CML.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/123/25/3951/1464319/3951.pdf

Reference48 articles.

1. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.;Rowley;Nature,1973

2. The biology of chronic myeloid leukemia.;Faderl;N Engl J Med,1999

3. Chronic myeloid leukaemia as a model of disease evolution in human cancer.;Melo;Nat Rev Cancer,2007

4. Perspectives on the development of a molecularly targeted agent.;Druker;Cancer Cell,2002

5. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.;Druker;N Engl J Med,2006

Cited by 184 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD26 Is Differentially Expressed throughout the Life Cycle of Infantile Hemangiomas and Characterizes the Proliferative Phase;International Journal of Molecular Sciences;2024-09-10

2. Immunophenotypic features of early haematopoietic and leukaemia stem cells;International Journal of Laboratory Hematology;2024-07-24

3. Cancer stem cells: advances in knowledge and implications for cancer therapy;Signal Transduction and Targeted Therapy;2024-07-05

4. Peripheral blood quantitation of CD26 positive leukemic stem cells as a predictor of tyrosine kinase inhibitor response in chronic myeloid leukemia;International Journal of Laboratory Hematology;2024-05-06

5. Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia;Cell Reports Medicine;2024-05